Published in Clin Exp Immunol on July 01, 2005
Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol (2006) 2.18
Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet (2012) 1.65
Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol (2008) 1.42
A diagnostic algorithm combining clinical and molecular data distinguishes Kawasaki disease from other febrile illnesses. BMC Med (2011) 1.21
Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol (2009) 1.03
Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol (2008) 1.01
Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet (2010) 0.96
Serum and urinary NGAL in septic newborns. Biomed Res Int (2014) 0.91
Kawasaki disease and subsequent risk of allergic diseases: a population-based matched cohort study. BMC Pediatr (2013) 0.91
Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice. Arthritis Rheum (2013) 0.89
Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med (2014) 0.88
Hospitalisation with infection, asthma and allergy in Kawasaki disease patients and their families: genealogical analysis using linked population data. PLoS One (2011) 0.86
Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol (2012) 0.83
Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children. Heart Vessels (2008) 0.79
Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness. PLoS One (2016) 0.77
GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med (2016) 0.76
Association of the resistin gene promoter region polymorphism with Kawasaki disease in Chinese children. Mediators Inflamm (2012) 0.75
A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics (1974) 9.97
[Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi (1967) 9.06
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res (2002) 6.37
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 5.76
Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr (2002) 2.06
Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem (1995) 2.01
The family of matrix metalloproteinases. Ann N Y Acad Sci (1994) 1.81
Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr (2000) 1.58
The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med (1976) 1.57
cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem (1995) 1.54
Endothelial dysfunction late after Kawasaki disease. Circulation (1996) 1.53
Kawasaki syndrome. Pediatr Clin North Am (1999) 1.53
Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett (1997) 1.52
Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol (2002) 1.51
Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation (2001) 1.43
Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr (2000) 1.39
Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol (2001) 1.38
Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics (2001) 1.18
Neutrophil elastase: path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol (2002) 1.14
The role of bacterial lipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis (1999) 1.05
Neopterin in clinical practice. Clin Chim Acta (1991) 1.04
Altered myocardial flow reserve and endothelial function late after Kawasaki disease. J Pediatr (2003) 1.03
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg (2002) 1.02
Retracted Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation (2001) 1.02
Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis (1998) 0.98
Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis (2000) 0.97
Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J (2001) 0.91
Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1). Biochem J (1997) 0.89
Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol (2001) 0.88
Leucocyte activation markers in clinical practice. Clin Chem Lab Med (1999) 0.87
Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki syndrome. Clin Chem (1993) 0.86
Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Paediatr (1999) 0.84
Elastase and granzymes during meningococcal disease in children: correlation to disease severity. Intensive Care Med (2005) 0.79
Structure at 2.8 A resolution of F1-ATPase from bovine heart mitochondria. Nature (1994) 15.84
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1997) 5.24
Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol (1994) 5.14
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med (1986) 4.49
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation (1999) 4.40
Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation (1995) 3.80
The relationship between managed care insurance and use of lower-mortality hospitals for CABG surgery. JAMA (2000) 3.75
Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med (1993) 3.42
Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature (1989) 3.36
Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest (1989) 3.34
Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation (1992) 3.04
Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet (1989) 2.86
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr (1996) 2.77
Developmental and neurologic effects of alpha-stat versus pH-stat strategies for deep hypothermic cardiopulmonary bypass in infants. J Thorac Cardiovasc Surg (2001) 2.70
Developmental and neurological status of children at 4 years of age after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. Circulation (1999) 2.67
Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ (2011) 2.60
In-hospital mortality for surgical repair of congenital heart defects: preliminary observations of variation by hospital caseload. Pediatrics (1995) 2.60
Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J (1998) 2.53
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood (2000) 2.51
Serum levels of interleukin-6 and acute phase responses. Lancet (1987) 2.44
Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation (1997) 2.41
Noninvasive tests in the initial evaluation of heart murmurs in children. N Engl J Med (1983) 2.39
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 2.38
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation (1997) 2.32
Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol (1992) 2.29
Gamma globulin re-treatment in Kawasaki disease. J Pediatr (1993) 2.13
Serum inflammatory proteins and cognitive decline in older persons. Neurology (2005) 2.11
[Anaphylactic reactions following insect stings: clinical aspects, course and treatment]. Ned Tijdschr Geneeskd (1993) 1.96
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol (1998) 1.91
Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord (2007) 1.89
The Pediatric Heart Network: a primer for the conduct of multicenter studies in children with congenital and acquired heart disease. Pediatr Cardiol (2006) 1.86
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr (1998) 1.84
Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum (2001) 1.84
Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg (1997) 1.75
Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med (1986) 1.74
Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a Web-based survey. Arthritis Care Res (Hoboken) (2012) 1.73
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 1.67
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost (2001) 1.65
Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J (2002) 1.65
Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med (1992) 1.65
Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ (2004) 1.65
Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally. Am J Cardiol (1999) 1.64
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Passive cigarette smoking and reduced HDL cholesterol levels in children with high-risk lipid profiles. Circulation (1997) 1.63
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax (2004) 1.63
C1-esterase inhibitor substitution in sepsis. Lancet (1992) 1.61
Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest (1998) 1.61
Cognitive development after the Fontan operation. Circulation (2000) 1.60
Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr (1991) 1.60
Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum (2006) 1.59
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
A new method for detecting endocytosed proteins. EMBO J (1988) 1.57
C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev (2000) 1.52
[Immunology in medical practice. XXXV. Screening of suspected immunodeficiency: diagnostic protocols for patients with opportunistic or recurrent severe infections, wasting and failure to thrive]. Ned Tijdschr Geneeskd (2000) 1.50
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to 111indium-labelled transferrin and circulating mediators. Thorax (1997) 1.48
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost (1996) 1.47
Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood (1995) 1.47
Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest (1987) 1.45
Proteolytic inactivation of alpha 1-antitrypsin and alpha 1-antichymotrypsin by neutrophils in arthritic joints. Arthritis Rheum (1993) 1.44
Identification of the subunits of F1F0-ATPase from bovine heart mitochondria. Biochemistry (1991) 1.43
Spectrum of renal anomalies in patients with Williams syndrome. J Pediatr (1991) 1.43
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost (2003) 1.41
Perioperative effects of alpha-stat versus pH-stat strategies for deep hypothermic cardiopulmonary bypass in infants. J Thorac Cardiovasc Surg (1997) 1.41
Hyperlipidemia in children and adolescents. Am Heart J (2001) 1.41
Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol (1998) 1.39
Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation (1994) 1.39
A review of the effects of multiple stressors on aquatic organisms and analysis of uncertainty factors for use in risk assessment. Crit Rev Toxicol (2001) 1.39
Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 1.38
Neutrophil and monocyte adherence to and migration across monolayers of cytokine-activated endothelial cells: the contribution of CD18, ELAM-1, and VLA-4. Blood (1991) 1.37
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr (1986) 1.34
CD18 activation epitopes induced by leukocyte activation. J Immunol (2001) 1.34
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol (1990) 1.34
Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods (1993) 1.33
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
Apoptosis of neutrophils. Acta Haematol (2004) 1.32
Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg (1997) 1.31
A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol (1981) 1.31
Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.30
Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun (2000) 1.30
Delayed cortical development in fetuses with complex congenital heart disease. Cereb Cortex (2012) 1.28
Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol (1997) 1.28
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood (1994) 1.28
Cognitive function and age at repair of transposition of the great arteries in children. N Engl J Med (1984) 1.26
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol (1996) 1.26
Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol (2003) 1.25
The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol (1999) 1.24
Purification and partial characterization of the b-type cytochrome from human polymorphonuclear leukocytes. J Biol Chem (1985) 1.23